Urinary Volatile Organic Compounds for Colorectal Cancer Screening: A Systematic Review and Meta-analysis
Overview
Authors
Affiliations
Background: The faecal immunochemical test (FIT) suffers from suboptimal performance and participation in colorectal cancer (CRC) screening. Urinary volatile organic compounds (VOCs) may be a useful alternative. We aimed to determine the diagnostic potential of urinary VOCs for CRC/adenomas. By relating VOCs to known pathways, we aimed to gain insight into the pathophysiology of colorectal neoplasia.
Methods: A systematic search was performed in PubMed, EMBASE and Web of Science. Original studies on urinary VOCs for CRC/adenoma detection with a control group were included. QUADAS-2 tool was used for quality assessment. Meta-analysis was performed by adopting a bivariate model for sensitivity/specificity. Fagan's nomogram estimated the performance of combined FIT-VOC. Neoplasm-associated VOCs were linked to pathways using the KEGG database.
Results: Sixteen studies-involving 837 CRC patients and 1618 controls-were included; 11 performed chemical identification and 7 chemical fingerprinting. In all studies, urinary VOCs discriminated CRC from controls. Pooled sensitivity and specificity for CRC based on chemical fingerprinting were 84% (95% CI 73-91%) and 70% (95% CI 63-77%), respectively. The most distinctive individual VOC was butanal (AUC 0.98). The estimated probability of having CRC following negative FIT was 0.38%, whereas 0.09% following negative FIT-VOC. Combined FIT-VOC would detect 33% more CRCs. In total 100 CRC-associated urinary VOCs were identified; particularly hydrocarbons, carboxylic acids, aldehydes/ketones and amino acids, and predominantly involved in TCA-cycle or alanine/aspartate/glutamine/glutamate/phenylalanine/tyrosine/tryptophan metabolism, which is supported by previous research on (colorectal)cancer biology. The potential of urinary VOCs to detect precancerous adenomas or gain insight into their pathophysiology appeared understudied.
Conclusion: Urinary VOCs hold potential for non-invasive CRC screening. Multicentre validation studies are needed, especially focusing on adenoma detection. Urinary VOCs elucidate underlying pathophysiologic processes.
Afzal A, Aranan Y, Roberts T, Covington J, Vidal L, Ahmed S BJS Open. 2025; 9(1).
PMID: 39972538 PMC: 11839406. DOI: 10.1093/bjsopen/zrae154.
Zhang Z, Liang X, Lin K, Deng Y, Liang Y Arch Dermatol Res. 2025; 317(1):401.
PMID: 39951040 DOI: 10.1007/s00403-025-03954-0.
Arasaradnam R, Krishnamoorthy A, Hull M, Wheatstone P, Kvasnik F, Persaud K Sensors (Basel). 2025; 25(3).
PMID: 39943238 PMC: 11820771. DOI: 10.3390/s25030599.
Ramirez W, Pillajo V, Ramirez E, Manzano I, Meza D Sensors (Basel). 2024; 24(23).
PMID: 39686404 PMC: 11645018. DOI: 10.3390/s24237868.
Mannucci A, Goel A Mol Cancer. 2024; 23(1):259.
PMID: 39558327 PMC: 11575410. DOI: 10.1186/s12943-024-02174-w.